0001127602-17-024713.txt : 20170802
0001127602-17-024713.hdr.sgml : 20170802
20170802150024
ACCESSION NUMBER: 0001127602-17-024713
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170731
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lerman Bradley E
CENTRAL INDEX KEY: 0001559405
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36820
FILM NUMBER: 17999532
MAIL ADDRESS:
STREET 1: MEDTRONIC, INC.
STREET 2: 710 MEDTRONIC PKWY MSLC300
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55432
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Medtronic plc
CENTRAL INDEX KEY: 0001613103
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 000000000
FISCAL YEAR END: 0424
BUSINESS ADDRESS:
STREET 1: 20 ON HATCH, LOWER HATCH STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 01135314381700
MAIL ADDRESS:
STREET 1: 20 ON HATCH, LOWER HATCH STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
FORMER COMPANY:
FORMER CONFORMED NAME: Medtronic Ltd
DATE OF NAME CHANGE: 20150112
FORMER COMPANY:
FORMER CONFORMED NAME: Medtronic Holdings Ltd
DATE OF NAME CHANGE: 20140711
FORMER COMPANY:
FORMER CONFORMED NAME: Kalani I Ltd
DATE OF NAME CHANGE: 20140709
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2017-07-31
0001613103
Medtronic plc
MDT
0001559405
Lerman Bradley E
710 MEDTRONIC PKWY MS LC300
MINNEAPOLIS
MN
55432
1
SVP General Counsel & Corp Sec
Ordinary Shares
2017-07-31
4
A
0
11910
0
A
59960
D
Stock Option (Right to Buy)
83.97
2017-07-31
4
A
0
47637
0
A
2018-07-31
2027-07-31
Ordinary Shares
47637
47637
D
Stock Option (Right to Buy)
83.97
2017-07-31
4
A
0
1191
0
A
2018-07-31
2027-07-31
Ordinary Shares
1191
1191
D
The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee.
These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.
/s/ Rhonda L. Ingalsbe, Attorney-in-fact
2017-08-01